ClinicalTrials.gg
WithdrawnNCT02512029Updated Feb 5, 2016

18F-AV-1451 PET Imaging in TBI

A Phase 1 interventional study of 18F-AV-1451 in Traumatic Brain Injury, sponsored by Avid Radiopharmaceuticals. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-02-05.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 908 studies in Brain Injuries, Traumatic with a site in United States — 211 open to participants now, 249 under way, 5 of them phase 3. Brain Injuries, Traumatic · United States.

Enrollment
617th of 649
0 · median 50
Started
2015
with 42 others
Phase 1
46 of 908
13 open now
Registered
365th of 908
by date

Among the 908 studies in Brain Injuries, Traumatic with a site in United States, this one is the 617th largest by enrollment of the 649 interventional ones that give a count, is one of 43 that started in 2015, is one of 46 in phase 1, and was the 365th registered.

Brain Injuries, Traumatic

1,722 studies on the registry are indexed under Brain Injuries, Traumatic; 448 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

211 of the 908 studies in Brain Injuries, Traumatic with a site in United States are open now. Recruiting first, the newest first:

206 more — sign in →

All 211 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Brain Injuries, Traumatic studies recruiting now, 122 (43%) set no upper age limit and 120 (42%) stop at 75 or younger; 40 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 908 studies in Brain Injuries, Traumatic with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate imaging characteristics of 18F-AV-1451 in subjects with subacute traumatic brain injury.

03

Conditions studied

  • Traumatic Brain Injury
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

TBI Subjects

Inclusion criteria

Inclusion Criteria:

TBI Subjects

  • Subjects that have consented and are currently enrolled in either Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI), Evaluation, Pathogenesis, and Outcome of Subjects with or Suspected Traumatic Brain Injury Protocol Number: CNS: 10-N-N122, or Evaluation and Diagnosis of Potential Research Subjects with Traumatic Brain Injury (TBI): Protocol Number: 11-N-0084
  • History of having sustained a TBI \< 6 weeks prior to enrollment
  • Can tolerate PET and MRI scan procedures

Control Subjects

  • ≥ 28
  • No significant history of cognitive impairment
  • No prior history of TBI
  • Can tolerate PET and MRI scan procedures

Exclusion criteria

Exclusion Criteria:

  • Have behavior dysfunction that is likely to interfere with imaging
  • Are claustrophobic or otherwise unable to tolerate the imaging procedure
  • Have current cardiovascular disease, or clinically significant abnormalities on screening
  • A history of additional risk factors for Torsades de Pointes (TdP) or are taking drugs that are known to cause -prolongation
  • Have a current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
  • Are females of who are not surgically sterile, not refraining from sexual activity or not using reliable methods of
  • Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the 18F-AV-1451 imaging session
  • Have current alcohol dependence or alcohol dependence within the past 1 year
  • Are currently participating in another interventional clinical trial
  • Have evidence of a penetrating brain injury
  • Have participated in contact sports in college or after high school age
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    TBI Subjects

    Subjects with history of recent subacute Traumatic Brain Injury (TBI) will receive a single IV injection, 370 megabecquerel (MBq) \[10 millicurie (mCi)\] of 18F-AV-1451 2 to 6 weeks following injury. They will return for a follow-up injection approximately 6 months following injury.

    Drug: 18F-AV-1451

  • Experimental
    Control

    Cognitively healthy volunteer subjects will receive a single IV injection, 370 megabecquerel (MBq) \[10 millicurie (mCi)\] of 18F-AV-1451.

    Drug: 18F-AV-1451

Interventions

06

What researchers measure

Primary outcomes

  1. TBI Biomarker Analysis

    18F-AV-1451 uptake will be compared in subjects with TBI and controls.

    Time frame: 75-105 minutes postinjection

  2. Relationship Between Clinical Presentation and Tau Deposition (MMSE)

    The relationship between 18F-AV-1451 uptake and clinical measures using Mini-Mental State Examination (MMSE).

    Time frame: 75-105 minutes postinjection

  3. Change in tau deposition over time

    Assess the rate of change of tau deposition as measured by 18F-AV-1451 uptake over time.

    Time frame: 6 months

  4. Relationship Between Clinical Presentation and Tau Deposition (BIS-11)

    The relationship between 18F-AV-1451 uptake and clinical measures using Barratt Impulsivity Scale 11 (BIS-11)

    Time frame: 75-105 minutes postinjection

07

Study locations

1 site
  • NIH Clinical Center
    Bethesda, Maryland 20892, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Apr 2017 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2015
First posted
Jul 30, 2015
Start
Oct 2015
Primary completionEst.
Apr 2017
CompletionEst.
Apr 2017
Last update
Feb 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02512029
Responsible party
Sponsor
First posted
Jul 30, 2015
Start date
Oct 2015
Primary completion
Apr 2017 (estimated)
Completion
Apr 2017 (estimated)
Last update
Feb 5, 2016

Study contacts

Chief Medical Officer
study chair · Avid Radiopharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion